IE56311B1 - Acridanone derivatives - Google Patents
Acridanone derivativesInfo
- Publication number
- IE56311B1 IE56311B1 IE2770/83A IE277083A IE56311B1 IE 56311 B1 IE56311 B1 IE 56311B1 IE 2770/83 A IE2770/83 A IE 2770/83A IE 277083 A IE277083 A IE 277083A IE 56311 B1 IE56311 B1 IE 56311B1
- Authority
- IE
- Ireland
- Prior art keywords
- signifies
- see diagramm
- lower alkyl
- group
- hydrogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
- C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
- C07D219/06—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
- C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
- C07D219/08—Nitrogen atoms
- C07D219/10—Nitrogen atoms attached in position 9
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K19/00—Liquid crystal materials
- C09K19/04—Liquid crystal materials characterised by the chemical structure of the liquid crystal components, e.g. by a specific unit
- C09K19/06—Non-steroidal liquid crystal compounds
- C09K19/08—Non-steroidal liquid crystal compounds containing at least two non-condensed rings
- C09K19/10—Non-steroidal liquid crystal compounds containing at least two non-condensed rings containing at least two benzene rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Tropical Medicine & Parasitology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Crystallography & Structural Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
Abstract
For the Contracting States BE CH DE FR GB IT LI LU NL SE 1. Acridanone derivatives of the general formula see diagramm : EP0110298,P20,F1 wherein the dotted line signifies an optional bond, R**1 signifies hydrogen, halogen or nitro, R**2 signifies hydrogen or lower alkyl, one of the symbols R**3 and R**4 signifies hydrogen or lower alkyl and the other together with R signifies an additional bond, A signifies lower alkylene, R**5 signifies a 5-membered, nitrogen-containig, optionally lower alkyl-substituted aromatic heterocycle, amino or a group see diagramm : EP0110298,P20,F2 or see diagramm : EP0110298,P20,F3 the symbol see diagramm : EP0110298,P20,F4 signifies a 5- or 6-membered, optionally lower-alkyl substituted saturated heterocycle which can contain as a ring member an oxygen or sulphur atom or the group >NH ou >N(B)n -A**1-R**6, B signifies the group -CO-, -COO- or -SO2 -, n signifies the number 0 or 1, A**1 signifies lower alkylene, R**6 signifies hydrogen, amino, lower alkylamino or di(lower alkyl)amino and R**7 signifies hydrogen or lower alkyl, and the residues denoted as lower contain 1 to 7 carbon atoms, and pharmaceutically acceptable acid addition salts thereof. For the Contracting State AT 1. A process for the manufacture of acridanone derivatives of the general formula see diagramm : EP0110298,P22,F1 wherein the dotted line signifies an optional bond, R**1 signifies hydrogen, halogen or nitro, R**2 signifies hydrogen or lower alkyl, one of the symbols R**3 and R**4 signifies hydrogen or lower alkyl and the other together with R signifies an additional bond, A signifies lower alkylene, R**5 signifies a 5-membered, nitrogen-containing, optionally lower alkyl-substituted aromatic heterocycle, amino or a group see diagramm : EP0110298,P23,F2 or see diagramm : EP0110298,P23,F3 the symbol see diagramm : EP0110298,P23,F4 signifies a 5- or 6-membered, optionally lower-alkyl substituted saturated heterocycle which can contain as a ring member an oxygen or sulphur atom or the group >NH ou >N(B)n -A**1-R**6, B signifies the group -CO-, -COO- or -SO2 -, n signifies the number 0 or 1, A**1 signifies lower alkylene, R**6 signifies hydrogen, amino, lower alkylamino or di(lower alkyl)amino and R**7 signifies hydrogen or lower alkyl, and the residues denoted as lower contains 1 to 7 carbon atoms, and pharmaceutically acceptable acid addition salts thereof, characterized by a) cyclizing a compound of the general formula see diagramm : EP0110298,P23,F5 wherein one of the symbols R**31 and R**41 signifies hydrogen or lower alkyl and the other signifies hydrogen, R**42 signifies hydrogen or lower alkyl, R**51 signifies a residue R**5, but does not contain a primary or secondary basic amino group, and X' signifies a leaving group, and R**1, R**2 and R**5 have the above significance, b) reacting a compound of the general formula see diagramm : EP0110298,P23,F6 wherein A, R**1, R**42 and R**51 have the above significance, with a compound of the general formula see diagramm : EP0110298,P23,F7 wherein X" signifies a leaving group and the dotted line and R**2 have the above significance, or c) reacting a compound of the general formula see diagramm : EP0110298,P23,F8 wherein Y(anion) signifies an anion and X signifies a leaving group, and A, R**1 and R**51 have the above significance, with a compound of the general formula see diagramm : EP0110298,P23,F9 wherein the dotted line, R, R**2, R**3 and R**4 have the above significance, or d) cleaving off the N-protecting group in a compound of the general formula see diagramm : EP0110298,P24,F10 wherein R**8 signifies a residue R**5 which contains a primary or secondary basic amino group blocked by a N-protecting group and the dotted line, R, R**1, R**2, R**3 and R**4 have the above significance, and e) if desired, converting a compound of formula I obtained into a pharmaceutically acceptable acid addition salt.
[EP0110298A1]
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH689682 | 1982-11-26 |
Publications (2)
Publication Number | Publication Date |
---|---|
IE832770L IE832770L (en) | 1984-05-26 |
IE56311B1 true IE56311B1 (en) | 1991-06-19 |
Family
ID=4316762
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IE2770/83A IE56311B1 (en) | 1982-11-26 | 1983-11-25 | Acridanone derivatives |
Country Status (24)
Country | Link |
---|---|
EP (1) | EP0110298B1 (en) |
JP (1) | JPS59108783A (en) |
KR (1) | KR840006653A (en) |
AR (1) | AR240934A1 (en) |
AT (1) | ATE34749T1 (en) |
AU (1) | AU565078B2 (en) |
BR (1) | BR8306513A (en) |
CA (1) | CA1258854A (en) |
CS (1) | CS235991B2 (en) |
DE (1) | DE3376832D1 (en) |
DK (1) | DK542383D0 (en) |
DO (1) | DOP1983004180A (en) |
ES (3) | ES527552A0 (en) |
FI (1) | FI79847C (en) |
HU (1) | HU192829B (en) |
IE (1) | IE56311B1 (en) |
IL (1) | IL70273A (en) |
MC (1) | MC1556A1 (en) |
NO (1) | NO160139C (en) |
NZ (1) | NZ206317A (en) |
PH (1) | PH19364A (en) |
PT (1) | PT77730B (en) |
ZA (1) | ZA838639B (en) |
ZW (1) | ZW23783A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2036198C1 (en) * | 1993-04-01 | 1995-05-27 | Товарищество с ограниченной ответственностью "Полисан" | N-METHYL- N- (α-D- GLUCOPYRANOSYL) -AMMONIUM -2-(ACRIDONE -9-ONE -10-YL) -ACETATE (CYCLOFERON) SHOWING INTERFEROGENIC, ANTIVIRAL AMONG THEM ANTI-HIV, ANTIPARASITIC, ANTIPROMOTER AND RADIOPROTECTIVE ACTIVITIES |
US7829578B1 (en) | 2005-12-12 | 2010-11-09 | Oregon Health & Science University | Aromatic ketones and uses thereof |
US8592447B2 (en) | 2006-11-13 | 2013-11-26 | Oregon Health & Science University | Acridone compounds |
US8598354B2 (en) | 2008-12-05 | 2013-12-03 | University Of South Florida | Compounds having antiparasitic or anti-infectious activity |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1068595A (en) * | 1964-06-08 | 1967-05-10 | Gevaert Photo Prod Nv | Colour photographic process |
DE1811409A1 (en) * | 1968-11-28 | 1970-06-18 | Bayer Ag | Preparations for combating insects, mites, rabbits and rodents |
-
1983
- 1983-11-01 CA CA000440203A patent/CA1258854A/en not_active Expired
- 1983-11-02 ZW ZW237/83A patent/ZW23783A1/en unknown
- 1983-11-16 CS CS838490A patent/CS235991B2/en unknown
- 1983-11-18 NZ NZ206317A patent/NZ206317A/en unknown
- 1983-11-18 IL IL70273A patent/IL70273A/en unknown
- 1983-11-18 ZA ZA838639A patent/ZA838639B/en unknown
- 1983-11-18 AU AU21488/83A patent/AU565078B2/en not_active Ceased
- 1983-11-22 DE DE8383111665T patent/DE3376832D1/en not_active Expired
- 1983-11-22 AT AT83111665T patent/ATE34749T1/en not_active IP Right Cessation
- 1983-11-22 EP EP83111665A patent/EP0110298B1/en not_active Expired
- 1983-11-23 HU HU834024A patent/HU192829B/en not_active IP Right Cessation
- 1983-11-24 DO DO1983004180A patent/DOP1983004180A/en unknown
- 1983-11-24 PH PH29883A patent/PH19364A/en unknown
- 1983-11-24 FI FI834321A patent/FI79847C/en not_active IP Right Cessation
- 1983-11-25 IE IE2770/83A patent/IE56311B1/en unknown
- 1983-11-25 BR BR8306513A patent/BR8306513A/en unknown
- 1983-11-25 NO NO834344A patent/NO160139C/en unknown
- 1983-11-25 KR KR1019830005590A patent/KR840006653A/en not_active Application Discontinuation
- 1983-11-25 ES ES527552A patent/ES527552A0/en active Granted
- 1983-11-25 PT PT77730A patent/PT77730B/en not_active IP Right Cessation
- 1983-11-25 DK DK5423/83A patent/DK542383D0/en not_active Application Discontinuation
- 1983-11-25 AR AR294930A patent/AR240934A1/en active
- 1983-11-25 MC MC831672A patent/MC1556A1/en unknown
- 1983-11-26 JP JP58221460A patent/JPS59108783A/en active Pending
-
1984
- 1984-07-16 ES ES534337A patent/ES8604213A1/en not_active Expired
- 1984-07-16 ES ES534338A patent/ES534338A0/en active Granted
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES8402833A1 (en) | Azolyl-methyl oxiranes, their preparation and use as medicaments and plant protecting agents. | |
ATE408597T1 (en) | ALIPHATIC NITROGEN CONTAINING FIVE-MEMBED RING COMPOUNDS | |
EP0313512A3 (en) | Benzothiadiazoles and their use in processes and compositions against plant diseases | |
ES8301981A1 (en) | Pyrroloquinoline and benzoquinolizine compounds and antimicrobial compositions | |
EP0639569A4 (en) | Novel heterocyclic compound. | |
NO180196C (en) | Analogous Process for Preparation of Therapeutically Active Amino and Nitro Containing Tricyclic Compounds | |
DK264880A (en) | PYRAZOLOQUINOLINES AND THEIR PREPARATION AND USE | |
IE56311B1 (en) | Acridanone derivatives | |
GB1213172A (en) | Dibenzothiazepine derivatives and production of the same | |
ES484679A1 (en) | Cyclic iminocarboxylic acid derivatives | |
ZA881810B (en) | Imidazole derivatives | |
DE3161895D1 (en) | 5-substituted-9-cyane-methylene-dithieno(3,4-b:4',3'-e) azepines, process for their preparation and pharmaceutical compositions containing them | |
GB921474A (en) | New phenthiazine derivatives | |
GB1012619A (en) | Improvements in or relating to dibenzocyclohepta-diene and -triene derivatives | |
ES8702877A1 (en) | Benzoic acid derivatives and process for their preparation | |
ES271204A1 (en) | Improvements in or relating to guanidine derivatives suitable for combating noxious organisms | |
EP0233287A4 (en) | 1,4-thiazine derivatives, process for their preparation, and cardiotonics containing the same. |